Pharmacodynamic data on antimalarials used in pregnancy are limited. Available data suggest that pharmacodynamic properties are often altered during pregnancy but the changes are not significant enough to require dosage…

Several high‐risk patient populations, including young children, pregnant women, and patients taking strong enzyme‐inducing drugs (e.g., rifampicin, efavirenz), have altered pharmacokinetics that result in less optimal exposure to antimalarial drugs.…